Overview
Donanemab and remternetug sit on this company’s node so pipeline and approved products stay distinct.
Scorecard
All companies- approved products +6
- phase 3 +3
- targets +2
- modalities +2
- regions +6
Donanemab is a monthly infused antibody for early Alzheimer’s disease after amyloid confirmation, with the same ARIA monitoring theme as other amyloid antibodies.
Remternetug is an investigational amyloid antibody. It is not approved. Trial eligibility is not a treatment recommendation.
Similar pages
not linked directly; found by shared links- RoadmapAnti-amyloid medicines
Shares EXPEDITION 3, Remternetug, Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- TargetAmyloid-beta
Shares Remternetug, Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyApoE testing
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyAnti-amyloid antibodies
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- TermARIA
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- IdeaAntibody trials that enrol mixed and comorbid disease
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- DiagnosisMild cognitive impairment
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- PersonAlois Alzheimer
Shares Alzheimer’s disease and the tag dementia-atlas.